October 23, 2017
OncoSec Medical reported phase II data from patients treated with ImmunoPulse IL-12 as a monotherapy versus ImmunoPulse IL-12 and the pembrolizumab for metastatic melanoma. OMS-I100 monotherapy and OMS-I102 combination with pembrolizumab studies included 51 and 22 patients, respectively. Results from OMS-I102 combination with pembrolizumab showed 50% (11/22) BORR observed at 24 weeks (42.9% [9/21] achieved RECIST v1.1 BORR). It also showed 41% (9/22) complete responders (CR), 9% (2/22) partial responders (PR) and 9% (2/22) stable disease (SD) for a total disease control rate of 59% (38.1% [8/21] achieved RECIST v1.1 durable CR). The data continue to support the rationale for a recently initiated global, open-label, phase IIb registration directed trial, PISCES/KEYNOTE-695.
June 6, 2016
Array BioPharma released results of a
phase III trial of binimetinib for NRAS-mutant
melanoma. In the trial, 402 patients with
NRAS-mutant melanoma were randomized
2:1 to receive binimetinib or dacarbazine,
respectively. The primary endpoint of PFS
was met, with a hazard ratio of 0.62, [95% CI
0.47-0.80] and a p-value of less than 0.001.
The median PFS on the binimetinib arm
was 2.8 months versus 1.5 months on the
dacarbazine arm. Importantly, an improvement
in median PFS in binimetinib-treated
patients was observed in the pre-specified
sub-group of patients who received prior
treatment with immunotherapy. The median
PFS on the binimetinib arm was 5.5 months
versus 1.6 months on the dacarbazine arm
[HR=0.46 (95% CI 0.26-0.81)]. Confirmed
overall response rate and disease control rate
were 15% (95% CI, 11-20%) and 58% (95% CI,
52-64%) for all patients receiving binimetinib,
respectively, versus 7% (95% CI, 3-13%) and
25% (95% CI, 18-33%) for patients receiving
dacarbazine, respectively. Grade 3/4 adverse
events reported in greater than or equal to
5% of patients receiving binimetinib included
increased creatine phosphokinase and hypertension.
The company plans to submit an
NDA in the next month.
December 7, 2015
Exelixis has issued results of a phase III
trial of Cotellic (cobimetinib) in patients
with previously untreated resectable, locally
advanced or metastatic melanoma carrying a
BRAF V600E or V600K mutation, in combination
with vemurafenib. In October, Exelixis
announced the coBRIM trial met its OS secondary
endpoint, demonstrating a statistically
significant increase in OS for the combination
of Cotellic and vemurafenib compared to vemurafenib
monotherapy. The median OS was
22.3 months for the combination of Cotellic
and vemurafenib v. 17.4 months for vemurafenib
alone, corresponding to a 30% reduction
in the rate of death for the combination
as compared to vemurafenib alone (hazard
ratio [HR]=0.70, 95% confidence interval [CI]
0.55-0.90, p=0.005). Ongoing study monitoring
did not identify any new safety signals. On
Nov. 10, the FDA approved Cotellic as a treatment
for patients with BRAF V600E or V600K
mutation-positive unresectable or metastatic
melanoma, in combination with vemurafenib.
Cotellic was first approved in Switzerland in
late August. The Cotellic approvals are based
on data from coBRIM, the phase III pivotal trial
conducted by Genentech in 495 patients with
previously untreated unresectable, locally
advanced or metastatic melanoma carrying a
BRAF V600 mutation. Genentech sponsored
the U.S. NDA and Roche sponsored the Swiss
regulatory application. Roche also filed a
Marketing Authorization Application (MAA)
with the EMA in late 2014, and the Committee
for Medicinal Products for Human Use issued
a positive recommendation on the MAA in
September of this year. Roche anticipates a
decision from the European Commission by
July 13, 2015
Novartis issued results of a phase III
study of with the combination of Tafinlar
(dabrafenib) and Mekinist (trametinib)
compared to Tafinlar monotherapy alone
for BRAF V600E/K mutation-positive
metastatic melanoma. COMBI-d is a pivotal,
phase III, randomized, double-blinded
study in patients with unresectable (stage
IIIC) or metastatic (stage IV) BRAF V600E/K
mutation-positive cutaneous melanoma.
The study randomized 423 patients. The final
OS analysis showed that the combination of
Tafinlar and Mekinist achieved a statistically
significant OS benefit compared to Tafinlar
monotherapy (median of 25.1 months v.
18.7 months; Hazard Ratio [HR] 0.71 [95%
Confidence Interval (CI), 0.55-0.92], p=0.011).
A 33% reduction in the risk of progression or
death was demonstrated with the combination
therapy compared to monotherapy (median
PFS of 11 months in the 211 patients receiving
combination therapy v. 8.8 months in
the 212 patients receiving monotherapy; HR
0.67 [95% CI, 0.53-0.84], p<0.001). The combination
achieved ORR of 69% compared to
53% for monotherapy [difference=15% (95%
CI, 6.0%-24.5%), p=0.001]. The median DoR
for the 144 responders receiving combination
therapy was 12.9 months [95% CI,
9.4-19.5] compared to 10.6 months in the
113 responders receiving monotherapy [95%
CI, 9.1-13.8]. The safety results were consistent
with the profile observed to date for the
combination and consistent with the profile
observed for Tafinlar monotherapy; no new
safety concerns were observed. Completion
of COMBI-d is a post-marketing requirement
for the FDA’s accelerated approval for the
combination in the U.S.
December 1, 2014
GlaxoSmithKline reported results of a
phase III study of trametinib (Mekinist)
and dabrafenib (Tafinlar) compared to
vemurafenib monotherapy in previously
untreated patients with BRAF V600E/K mutation-
positive metastatic melanoma. This phase
III, randomized (1:1), open-label study enrolled
704 patients globally. The study demonstrated
a 31% decrease in the risk of death for patients
treated with the trametinib and dabrafenib
combination compared to vemurafenib
(Hazard Ratio [HR] 0.69; 95% Confidence Interval
[CI] 0.53, 0.89; two-sided P=0.005). Median
OS for the vemurafenib arm was 17.2 months;
median OS for the combination arm had not
been reached. At 12 months, the rate of OS
was 72% for the combination arm and 65%
for the vemurafenib arm. Treatment with the
combination increased median progressionfree
survival to 11.4 months compared to 7.3
months for the vemurafenib arm. Overall, treatment
with the combination resulted in a 44%
reduction in risk of disease progression or death
(HR, 0.56; 95% CI 0.46, 0.69; two-sided P-value
<0.001) compared to vemurafenib. The objective
response rate was 64% (95% CI 59.1%,
69.4%) for the combination and 51% (95% CI
46.1%, 56.8%) for vemurafenib (P<0.001); the
median duration of response was 13.8 months
(95% CI 11.0, not reached) v. 7.5 months (95%
CI 7.3, 9.3), respectively. Additionally, 13% of
patients treated with the combination achieved
a complete response, compared to 8% of
patients in the vemurafenib arm.
August 5, 2013
OncoSec Medical released results of a phase II study of DNA IL-12 and electroporation for the treatment of advanced melanoma. The 24-week, single-arm, open-label, multi-center study enrolled 25 patients with stage III or IV cutaneous and in-transit metastatic melanoma. One treatment cycle consisted of three treatments applied to up to four lesions on days one, five and eight with a maximum dose of 1.5mg DNA IL-12 per treatment cycle. At day 90 following treatment, it was demonstrated that there was a significant decrease in circulating “exhausted” CD8/PD-1+ (p=0.0017) and CD8/CD69+ (p=0.008) T-cells. PD-1 is expressed in activated exhausted T cells, and blocking PD-1 is an emerging treatment modality for multiple cancers including melanoma. In addition, an increase in NK cell frequency and activation was also observed from baseline. It was also demonstrated that antigen-specific T-cell responses to melanoma were increased while other antibody responses were modulated and appeared to narrow over time. These data confirm the systemic effects of DNA IL-12 administered locally with electroporation. At 12 months, patients are moved to the follow-up phase of the study and will be followed for up to five years for safety.
November 28, 2012
OncoSec Medical issued preliminary results from a phase II trial of ImmunoPulse for the treatment of metastatic melanoma. This single-arm, open-label and multi-center study has enrolled 13 patients with stage III or IV cutaneous and in-transit metastatic melanoma, of 25 patients expected. Subjects received a maximum dose of 1.5mg of DNA IL-12 via ImmunoPulse on days one, five and eight, applied to up to four lesions. Subjects also received electroporation treatment. Results suggested that ImmunoPulse is able to induce regression or stabilization of distant untreated metastases following a single cycle of treatment. Ninety-five percent of treated lesions demonstrated response at day 39 (5% progressive disease, 14% stable disease (SD), 42% partial response (PR), 39% complete response (CR)). All treated lesions at day 90 (5% SD, 50% PR, 45% CR), and at day 180 (33% PR, 67% CR) demonstrated a response. At day 180, two subjects were evaluable for the primary endpoint of objective overall response (ORR). One patient has a confirmed stable disease, and the second patient has a confirmed complete response of all treated and untreated lesions. ImmunoPulse and DNA IL-12 were well tolerated. The most frequent adverse events were generally limited to transient pain related to electroporation treatment. OncoSec Medical will continue the phase II study, which it expects to be completed by the end of 2012.
November 5, 2012
Specialised Therapeutics Australia issued results from a phase III comparative trial of Abraxane versus standard chemotherapy for the treatment of metastatic melanoma. This randomized, open-label, international study enrolled 529 chemotherapy-naïve patients. Subjects received either Abraxane 150mg/m2 weekly for three out of four weeks, or dacarbazine 1000mg/m2 every three weeks. The Abraxane arm showed statistically significant improvement in progression-free survival (PFS) (4.8 months) compared to patients receiving dacarbazine chemotherapy (2.5 months) (HR:0.792; 95.1% CI: 0.631, 0.992; P=0.044). Data shows overall survival trends in favor of the Abraxane arm (12.8 months) compared to dacarbazine (10.7 months) (HR:0.831; 99.9% CI: 0.578, 1.196; P=0.094). The drug was well tolerated. The most frequent adverse events were neuropathy and neutropenia. Specialised Therapeutics Australia hopes to have Abraxane approved by the Therapeutic Goods Administration in Australia by 2014.
July 18, 2011
Cytavis reported results from a phase II trial of Aviscumine (CY503) for the treatment of melanoma. This open label trial enrolled 31 subjects with Stage IV unresectable metastatic melanoma after antineoplastic treatment failure. The subjects received subcutaneous injections of Aviscumine 350 ng twice weekly. The progression-free survival rate after three months was 32%, the one year-survival rate was 45% and median overall survival time (mOS) was 11 months. This compares favorably to standard therapy, Dacarbazine, which has a usual one-year-survival rate of 30% and mOS between six and eight months.
January 24, 2011
Plexxikon reported positive interim results from a phase III trial of PLX4032 for melanoma. This global, randomized, open-label, controlled trial, BRIM3, enrolled 675 subjects with previously untreated mutation-positive metastatic melanoma. The subjects were randomized to receive either: PLX4032 960 mg orally twice daily, or dacarbazine 1000 mg/m2 intravenously every three week until disease progression. Interim data showed that the co-primary endpoints, overall survival and progression free survival, were improved with the PLX4032 treatment arm when compared with the dacarbazine treatment arm. The safety profile was consistent with the previous PLX4032 studies.
November 15, 2010
Plexxikon issued positive preliminary results from a phase II trial of PLX4032 for the treatment of metastatic melanoma. This open label, single-arm trial. BRIM-2, enrolled 132 subjects with previously treated metastatic melanoma and the BRAF V600 mutation. The subjects received PLX4032 orally at a dose of 960 mg twice-daily. Data show a confirmed response rate of 52%, including three confirmed complete responses and 66 confirmed partial responses (tumor shrinkage of at least 30 percent) In addition, 39 subjects had stable disease. The median progression-free survival (PFS) was 6.2 months, compared to historical PFS of less than two months. The median duration of response was 6.8 months. Median overall survival has not yet been reached.
Provectus reported positive preliminary results from a phase II trial of PV-10, an injectable formulation of Rose Bengal for the treatment of metastatic melanoma. This open label trial enrolled 80 subjects with Stage III/IV melanoma in the US and Australia. Provecta was injected in up to 20 tumors and response was to be observed for one year. The primary endpoint was objective response rate (ORR). An ORR was observed in 49% of subjects, and 71% achieved locoregional disease control (stable disease or better) in their injected lesions. A mean Progression Free Survival of 11.7 months was observed among subjects achieving an ORR. A Complete Response of PV-10 injected lesions was achieved in 24% of subjects, Partial Response in 25% and Stable Disease in 18% of subjects, with 23% of subjects experiencing disease progression. The mean Progression Free Survival was 8.2 months for all subjects.
October 4, 2010
Zymogenetics reported results from a phase IIa trial evaluating recombinant Interleukin 21 (IL-21) for metastatic melanoma. This open-label, multi-center study enrolled 40 subjects who were placed in one of three cohorts: Cohort One received 50 mcg/kg/day by outpatient intravenous bolus injection daily for five days in weeks one, three and five of an eight week treatment cycle. Cohort Two received 30 mcg/kg/day in the same schedule, and Cohort Three received 50 mcg/kg/day daily for five days in weeks one and three of a six week treatment cycle. Thirty-nine of the 40 subjects were evaluable for response. The overall response rate was 23% and the median progression-free survival was 4.3 months. The median overall survival was 12.4 months, and 53% of subjects had survived to 12 months.
August 30, 2010
Plexxikon and Roche issued positive results from a phase I extension evaluating PLX4032 (RG7204) for the treatment of BRAF V600E positive metastatic melanoma. A total of 32 subjects received PLX4032 at 960 mg twice daily until disease progression. Data showed an 81% response rate by RECIST criteria, including two complete responses and 24 partial responses (tumor shrinkage of at least 30%). In the entire population, the estimated median progression-free survival extended more than seven months. Sixteen subjects are still on study. Drug-related adverse events were predominantly mild in severity and included rash, joint pain, photosensitivity and fatigue.
June 14, 2010
Bristol-Myers Squibb reported positive results from a phase III trial of ipilimumab for the treatment of metastatic melanoma. This international, randomized, double-blind study (202) enrolled 676 treatment experienced subjects with unresectable Stage III or IV metastatic melanoma who were HLA-A2+. The subjects received ipilimumab plus a gp100 peptide vaccine (3 mg/kg and 1mg/kg every three weeks for four doses), ipilimumab (3 mg/kg every three weeks for four doses) plus placebo or gp100 plus placebo. The primary endpoint was comparison of overall survival (OS) between ipilimumab plus gp100 versus gp100 alone. The median OS was 10, 10.1 and 6.4 months for the ipilimumab plus gp100, ipilimumab alone and gp100 alone groups, respectively (p≡ 0.0004 and 0.0026). At one year, approximately 46% of subjects treated with ipilimumab were alive compared to 25% of subjects treated with gp100 alone. At two years, approximately 24% of the subjects treated with ipilimumab were alive compared to 14% of patients treated with gp100 alone.
May 31, 2010
Provecta released positive interim results from a phase II trial of PV-10, an injectable formulation of Rose Bengal, for the treatment of metastatic melanoma. A total of 80 subjects with Stage III/IV melanoma were enrolled across the U.S. and Australia. Following initial treatment of 1-20 cutaneous, subcutaneous or nodal lesions, new or incompletely responsive lesions could be retreated at weeks 8, 12 or 16, with follow-up at 52 weeks. The primary end-point was objective response (OR) of injected lesions. These results are from the first 40 subjects completing treatment. Objective Response of PV-10 injected lesions was achieved in 61% of subjects, with a Complete Response (CR) in 33% of subjects and locoregional disease control (Stable Disease, SD) in 79% of subjects. The mean progression free survival (PFS) was 8.5 months for all subjects, while the OR cohort had a significantly longer PFS, estimated to be at least 11.1 months versus 2.8 months or less for SD or Progressive Disease subjects. Adverse events were mild to moderate.
January 7, 2008
Cephalon reported positive results from a phase III trial of Treanda for the treatment of chronic lymphocytic leukemia (CLL). This randomized, international, multicenter, open-label study enrolled three-hundred and five subjects. It was designed to compare Treanda to chlorambucil. The subjects received Treanda (100 mg /M2 on days one and two) or chlorambucil (0.8 mg/kg on days one and fifteen) for up to six treatment cycles. The co-primary endpoints, overall response rate and progression-free survival, were both achieved. Overall response rate was significantly higher with Treanda than with chlorambucil (68% versus 39%; p<0.0001) with a strong complete response rate of 30% compared to 2%, a nodular partial response of 10% compared to 3%, and a partial response of 28% compared to 34%, respectively. Treanda significantly improved progression-free survival compared to chlorambucil (median 21.7 months versus 9.3 months, respectively; p<.0001). The median duration of response in the Treanda arm was 18.9 months compared to 6.1 months in the chlorambucil arm. An NDA is currently under review by the FDA.
Gloucester reported positive preliminary results from a phase II trial of romidepsin for the treatment of cutaneous t-cell lymphoma (CTCL) at the American Society of Hematology (ASH) Annual Meeting. Subjects enrolled in this non-randomized, open-label, single-arm international study received romidepsin at a dose of 14 mg/m(2), intravenously over four hours, on days one, eight and fifteen of a twenty-eight day cycle. The duration was six cycles, although those subjects who had an objective response or stable disease were eligible to continue therapy until disease progression. Of seventy- three evaluable subjects, an overall response rate of 37% was reported, with four complete responses, twenty-three partial responses and forty reports of stable disease. Six subjects had progressive disease. Of the subjects with severe pruritus at baseline, 37% reported significant relief. In addition, 38% of the subjects who exhibited any pruritus at baseline reported significant relief from symptoms. Treatment was determined to be safe and well tolerated. Based on the results, this phase II trial continues as planned.
Medarex and Bristol-Myers Squibb announced mixed top-line results from three phase III registrational trials (008, 022, 007) evaluating ipilimumab monotherapy for the treatment of metastatic melanoma. These international trials included an open-label, single arm trial (008) evaluating overall response rate in one hundred and fifty-five subjects who progressed on or following standard treatment; a randomized, double-blind trial (022) evaluating the efficacy of three dose levels of ipilimumab in two hundred and sixteen subjects who were previously treated, relapsed or failed to respond to experimental treatment or were unable to tolerate currently approved therapies; and a randomized, double-blind, placebo-controlled trial (007) in one-hundred and sixteen subjects comparing the safety of ipilimumab, with or without prophylactic oral budesonide (primarily evaluating the rate of grade 2+ diarrhea). The results from study 008, conducted under a SPA, did not meet the primary endpoint, which was to rule out a best objective response rate of less than ten percent. However, the totality of data from the trials included a clear dose response effect observed in study 022 and best objective response rates across the three studies ranging from mid-single digits to mid-teens as determined by independent radiology review. The objective responses included complete and partial responses. Medarex and BMS were planning to meet with the regulatory authorities and file for US approval by the first half of 2008.
January 24, 2002
Phase III trial results indicate that a combination therapy consisting of histamine and interleukin-2 (IL-2) is well tolerated and improves the survival of advanced malignant melanoma subjects. In the multicenter trial, 305 subjects with stage IV melanoma were randomly assigned to receive IL-2, or IL-2 plus histamine. The IL-2/histamine combination resulted in a median survival of 283 days in subjects with metastases to their livers, compared to 154 days with IL-2 alone. For all randomized subjects entering the trial, the combination produced a median survival of 272 days, compared to 245 days for the IL-2-treated group. At 24 months follow-up, 25% of subjects receiving the histamine/IL-2 combination were alive, versus 17% of subjects receiving IL-2 alone. The trial was sponsored by Maxim Pharmaceuticals.